Kuguacin J, a Triterpeniod from Momordica Charantia Leaf, Modulates the Progression of Androgen-independent Human Prostate Cancer Cell Line, PC3
Overview
Toxicology
Authors
Affiliations
In this study, we focused on the in vitro effects of Kuguacin J (KuJ), a purified component of bitter melon (Momordica charantia) leaf extract (BMLE), on the androgen-independent human prostate cancer cell line PC3 and the in vivo effect of dietary BMLE on prostate carcinogenesis using a PC3-xenograph model. KuJ exerted a strong growth-inhibitory effect on PC3 cells. Growth inhibition was mainly through G1-arrest: KuJ markedly decreased the levels of cyclins (D1 and E), cyclin-dependent kinases (Cdk2 and Cdk4) and proliferating cell nuclear antigen. Interestingly, KuJ also dramatically decreased the levels of survivin expressed by PC3 cells. In addition, KuJ exerted anti-invasive effects on PC3 cells, significantly inhibiting migration and invasion: KuJ inhibited secretion of the active forms of MMP-2, MMP-9 and uPA by PC3 cells. In addition, KuJ treatment significantly decreased the expression of membrane type 1-MMP (MT1-MMP) by PC3 cells. In vivo, 1% and 5% BMLE in the diet resulted in 63% and 57% inhibition of PC3 xenograft growth without adverse effect on host body weight. Our results suggest that KuJ is a promising new candidate chemopreventive and chemotherapeutic agent for prostate cancer.
Arjsri P, Srisawad K, Semmarath W, Umsumarng S, Rueankham L, Saiai A Front Pharmacol. 2023; 14:1243727.
PMID: 38026959 PMC: 10667455. DOI: 10.3389/fphar.2023.1243727.
Hussain F, Hafeez J, Khalifa A, Naeem M, Ali T, Eed E Am J Transl Res. 2022; 14(6):3824-3839.
PMID: 35836841 PMC: 9274573.
Bitter Melon (), a Nutraceutical Approach for Cancer Prevention and Therapy.
Sur S, Ray R Cancers (Basel). 2020; 12(8).
PMID: 32726914 PMC: 7464160. DOI: 10.3390/cancers12082064.
Khan M, Abutaha N, Nasr F, Alqahtani A, Noman O, Wadaan M BMC Complement Altern Med. 2019; 19(1):184.
PMID: 31340810 PMC: 6657154. DOI: 10.1186/s12906-019-2599-0.
Mapoung S, Suzuki S, Fuji S, Naiki-Ito A, Kato H, Yodkeeree S Cancer Sci. 2018; 110(2):596-607.
PMID: 30499149 PMC: 6361605. DOI: 10.1111/cas.13897.